secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2024-11-27T23:59:59+00:00
Accession:  0000950170-24-131263
Event type: debt
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus secures $22M mortgage and announces realignment: 60% cost cut, FY25 cash burn ~$100M
--------------------------------------------------------------------------------

- $22M non-amortizing mortgage backed by Berkeley CMC facility and Vacaville land; net proceeds $20M after costs and reserve.
- Interest 12% Year 1, 13% Year 2, paid 50% cash and 50% common stock; 153,003 shares issued as first month interest and fees.
- Strategic Operational Realignment: 60% reduction in external expenditures; CMC transitioned to fee-for-service business.
- FY 2025 cash burn projected at ~$100M, pending finalization of additional strategic transactions.
- Focus on botensilimab/balstilimab (BOT/BAL) in MSS colorectal cancer for late-stage development and registration pathways.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000095017024131263/0000950170-24-131263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000095017024131263/agen-20241126.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-131263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer